Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Lung Cancer Treatment Market

Lung Cancer Treatment Market Trends

Report ID: GMI5708
Published Date: May 2023
Report Format: PDF

Download Free Sample

Lung Cancer Treatment Market Trends

Increasing use of combination therapy in oncology treatment is the current trend. Combination therapies involve using multiple treatments such as chemotherapy and immunotherapy, to improve outcomes in lung cancer patients. This approach has shown promising results in clinical trials and is expected to become more widely used in the coming years. For example, the combination of the chemotherapy drug cisplatin with the immunotherapy drug pembrolizumab has been shown to be effective in treating non-small cell lung cancer (NSCLC).

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for lung cancer treatment was valued at USD 15.70 billion in 2022 and will record a 12.4% CAGR between 2023 and 2032.

The targeted therapy segment had the highest revenue share of 36.6% in 2022 as it is designed to treat patients with specific genetic mutations or abnormalities.

North America lung cancer treatment market size was USD 7.17 billion in 2022 due to several factors that contribute to its growth and development, owing to the growing aging population, and technological advancements for lung cancer treatment.

Merck KGaA, GlaxoSmithKline plc., Pfizer Inc., Johnson & Johnson Services, Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Church & Dwight Co., Inc., and Sun Pharmaceutical Industries Ltd.